164 related articles for article (PubMed ID: 8205007)
1. Management of chronic myeloid leukaemia.
Goldman JM
Blood Rev; 1994 Mar; 8(1):21-9. PubMed ID: 8205007
[No Abstract] [Full Text] [Related]
2. [Chronic myeloid leukemia. New prospects for marrow autotransplantation].
Carella AM; Carlier P; Nati S; Congiu A; Pierluigi D; Raffo MR
Haematologica; 1991 Jun; 76 Suppl 3():337-51. PubMed ID: 1684348
[No Abstract] [Full Text] [Related]
3. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Hochhaus A; Heinze B
Blood; 1994 Dec; 84(12):4064-77. PubMed ID: 7994025
[TBL] [Abstract][Full Text] [Related]
4. [Complete cytogenetic remission of chronic myeloid leukemia with low-dose interferon alfa-2b and monthly high-dose busulfan].
Armenta D; Espallargas C; Paz A; Rodríguez Martorel J; Ladines R; Alvarez C; Román J; Andrés P
Sangre (Barc); 1996 Dec; 41(6):465-7. PubMed ID: 9148424
[TBL] [Abstract][Full Text] [Related]
5. Extramedullary blast crisis in chronic myeloid leukemia.
Specchia G; Palumbo G; Pastore D; Mininni D; Mestice A; Liso V
Leuk Res; 1996; 20(11-12):905-8. PubMed ID: 9009247
[TBL] [Abstract][Full Text] [Related]
6. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Elmaagacli AH; Beelen DW; Schaefer UW
Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
[TBL] [Abstract][Full Text] [Related]
7. The management of chronic myeloid leukaemia--a case history.
Sureda A; Hernández-Bronchud M
Ann Oncol; 1997 Jan; 8(1):91-6. PubMed ID: 9093713
[No Abstract] [Full Text] [Related]
8. Tetrasomy of Philadelphia chromosome in myeloblastic crisis of chronic myelogenous leukemia.
Oikawa H; Utsugisawa T; Murai K; Narigasawa Y; Miyairi Y; Shimosegawa K; Suzuki T; Kuriya S
Int J Hematol; 1995 Jun; 61(4):229-30. PubMed ID: 8547613
[No Abstract] [Full Text] [Related]
9. [Chronic myeloid leukemia: current pathogenetic aspects and new therapeutic approaches (a foreign literature review)].
Petukhov VI; Strozha IL; Bondare DK
Ter Arkh; 2001; 73(12):96-101. PubMed ID: 11858124
[No Abstract] [Full Text] [Related]
10. An accelerrated-phase CML patient with e19a2 junction of BCR/ABL gene - the first case of transplanted CML with micro bcr.
Polák J; Koza V; Cetkovský P; Haskovec C
Bone Marrow Transplant; 2000 May; 25(10):1109-10. PubMed ID: 10828875
[No Abstract] [Full Text] [Related]
11. [The assessment of therapeutic success in chronic myeloid leukemia].
Griesshammer M; Hehlmann R; Heimpel H
Dtsch Med Wochenschr; 1995 Apr; 120(17):620-5. PubMed ID: 7537652
[No Abstract] [Full Text] [Related]
12. A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
Haematologica; 1992; 77(3):204-14. PubMed ID: 1427426
[TBL] [Abstract][Full Text] [Related]
13. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
Hehlmann R; Heimpel H; Kolb HJ; Heinze B; Hochhaus A; Griesshammer M; Pralle H; Queisser WP; Essers U; Falge C
Leuk Lymphoma; 1993; 11 Suppl 1():159-68. PubMed ID: 8251890
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach.
Jehn U; Pötscher C; Heinemann V
Leuk Lymphoma; 1995 Sep; 19(1-2):153-7. PubMed ID: 8574162
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha 2a therapy in CML: disappearance of BCR/ABL transcript in a case of long-lasting continuous cytogenetic conversion.
Pardini S; Addis M; Dore F; Bonfigli S; Nieddu RM; Galanello R; Longinotti M; Pau MG
Haematologica; 1994; 79(6):540-1. PubMed ID: 7896213
[TBL] [Abstract][Full Text] [Related]
16. Treatment choices in chronic myelogenous leukemia.
Ready N; Freeman NJ; Carvalho A
Hosp Pract (Off Ed); 1992 Sep; 27(9A):95-8, 101. PubMed ID: 1522171
[No Abstract] [Full Text] [Related]
17. FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
Martinelli G; Testoni N; Zuffa E; Visani G; Zinzani PL; Zaccaria A; Farabegoli P; Arpinati M; Amabile M; Tura S
Leuk Lymphoma; 1996 Jun; 22(1-2):173-6. PubMed ID: 8724545
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
Nese M; de Bellis R; Urtiarte R; Di Landro J
Sangre (Barc); 1994 Jun; 39(3):183-6. PubMed ID: 7940047
[TBL] [Abstract][Full Text] [Related]
19. The combination of hydroxyurea and leucapheresis in the treatment of chronic myeloid leukaemia in pregnancy.
Fitzgerald JM; McCann SR
Clin Lab Haematol; 1993; 15(1):63-5. PubMed ID: 8472499
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study of chronic myelogenous leukemia].
Shibata A
Nihon Naika Gakkai Zasshi; 1993 Sep; 82(9):1318-30. PubMed ID: 8245626
[No Abstract] [Full Text] [Related]
[Next] [New Search]
